Supercharging Immunotherapy

fancy black and blue t-cell 3d scientific images immune system

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

6 Jan 2020

HOOKIPA has made strong progress in its collaboration with Gilead for novel…

30 Dec 2019

First patient has been dosed in a Phase 1/2 clinical trial of HB-201, an…

12 Nov 2019

HOOKIPA reports its financial results for the third quarter ended September…

31 Oct 2019

HOOKIPA announced its participation at two upcoming conferences in November.

25 Sep 2019

Christine D. Baker has joined HOOKIPA as Chief Business Officer (CBO) and…

19 Sep 2019

HOOKIPA will present the anti-cancer impact of its TheraT® technology in four…

all news

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

Supercharging Immunotherapy

Our Mission

News

HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines…

HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-201 …

HOOKIPA Pharma Reports Third Quarter 2019 Financial Results and Provides a…

HOOKIPA Pharma to Present at Upcoming Conferences in November

HOOKIPA Announces Key Hires to its Executive Team

HOOKIPA to Present Data Demonstrating the Potential of its TheraT® Technology…

Our Pipeline

Careers